Health and dental benefits provider Green Shield Canada (GSC) has made an investment in GenXys – a Canadian software developer specializing in pharmacogenomics.
Pharmacogenomics is the study of genes, and how they affect a patient’s response to drugs. GSC’s investment in GenXys’ pharmacogenomics technology will allow the two to collaborate on new products that will launch later this year. The products are aimed at helping healthcare professionals make more informed prescriptions, while decreasing adverse drug reactions and improving health outcomes for patients.
“GenXys stood out as a forward-thinking partner that shared our commitment to solving complex health challenges,” said GSC EVP of digital, innovation, and brand experience David Willows. “GSC has a long history of measuring the value of health benefits spending, and we look forward to exploring the role of pharmacogenomics in maximizing patient health outcomes and advancing the specific value of drug spend.”
“We are excited to be working with the GSC team as we shape the next stages of the pharmacogenomics story,” commented GenXys CEO Karl Pringle. “Our partnership opens the door to a wide range of new possibilities.”
GSC additionally announced that it would publish the results of its study – co-produced with its health benefits management solutions division HBM+ – later this summer. The study looks into the impact of pharmacogenomics on over 200 outpatients who have been diagnosed with major mental health conditions.
Earlier this month, GSC announced that it would collaborate with digital pharmacy PocketPills to create solutions to improve patients’ access to pharmacists and allow them to manage their medications.
